Defense-in-depth, especially at both the beginning and ends of the supply chain. All US pharmacies (retail and otherwise) should be required to capture a random sample of 0.1% of stock to the FDA for comprehensive mass spec characterization processed at federal labs with data released to the public openly. This data must be correlated with complementary point-of-production batch sampling. The data should agree, and would annihilate cheating, scamming, negligent, and incompetent manufacturers from harming patients.